XERIS BIOPHARMA HOLDINGS, INC. Other Nonoperating Income (Expense)
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Other Nonoperating Income (Expense) of -$36.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$36.27M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for the quarter ending 2026-03-31 was -$5.68M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for the quarter ending 2025-12-31 was -$5.69M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$6.11M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for fiscal 2025 was -$24.34M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for fiscal 2024 was -$23.46M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for fiscal 2023 was -$19.49M.
- XERIS BIOPHARMA HOLDINGS, INC. other nonoperating income (expense) for fiscal 2022 was -$14.14M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.27M 10-Q · filed 2026-08-06 | -$41.96M 10-Q · filed 2026-08-06 | -$47.65M derived: sum of 3 quarters · filed 2026-08-06 | -$53.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$5.68M 10-Q · filed 2026-05-07 | -$11.37M derived: sum of 2 quarters · filed 2026-05-07 | -$17.48M derived: sum of 3 quarters · filed 2026-05-07 | -$23.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.80M derived: sum of 2 quarters · filed 2026-03-02 | -$18.21M derived: sum of 3 quarters · filed 2026-08-06 | -$24.34M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$6.11M 10-Q · filed 2025-11-06 | -$12.52M derived: sum of 2 quarters · filed 2026-08-06 | -$18.65M 10-Q · filed 2025-11-06 | -$25.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$6.41M 10-Q · filed 2026-08-06 | -$12.54M 10-Q · filed 2026-08-06 | -$19.33M derived: sum of 3 quarters · filed 2026-08-06 | -$25.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$6.13M 10-Q · filed 2026-05-07 | -$12.92M derived: sum of 2 quarters · filed 2026-05-07 | -$19.09M derived: sum of 3 quarters · filed 2026-05-07 | -$25.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$12.96M derived: sum of 2 quarters · filed 2026-03-02 | -$19.03M derived: sum of 3 quarters · filed 2026-03-02 | -$23.46M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$6.17M 10-Q · filed 2025-11-06 | -$12.24M derived: sum of 2 quarters · filed 2025-11-06 | -$16.67M 10-Q · filed 2025-11-06 | -$20.45M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$6.07M 10-Q · filed 2025-08-07 | -$10.50M 10-Q · filed 2025-08-07 | -$14.28M derived: sum of 3 quarters · filed 2026-03-02 | -$21.90M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$4.43M 10-Q · filed 2025-05-08 | -$8.21M derived: sum of 2 quarters · filed 2026-03-02 | -$15.83M derived: sum of 3 quarters · filed 2026-03-02 | -$20.36M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.40M derived: sum of 2 quarters · filed 2026-03-02 | -$15.94M derived: sum of 3 quarters · filed 2026-03-02 | -$19.49M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$7.61M 10-Q · filed 2024-11-08 | -$12.15M derived: sum of 2 quarters · filed 2024-11-08 | -$15.71M 10-Q · filed 2024-11-08 | -$13.81M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$4.54M 10-Q · filed 2024-08-08 | -$8.10M 10-Q · filed 2024-08-08 | -$6.19M derived: sum of 3 quarters · filed 2025-03-06 | -$9.58M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$3.56M 10-Q · filed 2024-05-09 | -$1.66M derived: sum of 2 quarters · filed 2025-03-06 | -$5.04M derived: sum of 3 quarters · filed 2025-03-06 | -$12.65M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.49M derived: sum of 2 quarters · filed 2025-03-06 | -$9.10M derived: sum of 3 quarters · filed 2025-03-06 | -$14.14M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$3.39M 10-Q · filed 2023-11-09 | -$11.00M derived: sum of 2 quarters · filed 2023-11-09 | -$16.05M 10-Q · filed 2023-11-09 | -$18.57M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$7.61M 10-Q · filed 2023-08-08 | -$12.66M 10-Q · filed 2023-08-08 | -$15.18M derived: sum of 3 quarters · filed 2024-03-06 | -$16.83M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$5.05M 10-Q · filed 2023-05-09 | -$7.57M derived: sum of 2 quarters · filed 2024-03-06 | -$9.22M derived: sum of 3 quarters · filed 2024-03-06 | -$10.95M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$4.17M derived: sum of 2 quarters · filed 2024-03-06 | -$5.90M derived: sum of 3 quarters · filed 2024-03-06 | -$7.57M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$1.65M 10-Q · filed 2022-11-09 | -$3.38M derived: sum of 2 quarters · filed 2022-11-09 | -$5.05M 10-Q · filed 2022-11-09 | -$7.56M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$1.73M 10-Q · filed 2022-08-10 | -$3.40M 10-Q · filed 2022-08-10 | -$5.91M derived: sum of 3 quarters · filed 2022-08-10 | -$8.17M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$1.67M 10-Q · filed 2022-05-11 | -$4.18M derived: sum of 2 quarters · filed 2022-05-11 | -$6.44M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$4.77M derived: sum of 2 quarters · filed 2022-03-11 | -$7.70M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$2.26M 10-Q · filed 2021-11-10 | -$5.19M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |